Company intelligence / Profile preview

Onego Bio

Helsinki, Uusimaa, Finland

Ownership: Private
Employees: ~21
Development stage: Preclinical

Overview

Onego Bio has developed and scaled a precision fermentation process to produce animal-free egg white protein (Bioalbumen®), which is bioidentical to chicken-derived ovalbumin. The product matches traditional egg whites in nutrition and functionality but offers significant sustainability benefits. The company has filed for GRAS status with the FDA and is building large-scale manufacturing capacity in the US

Modalities: Recombinant proteinPrecision fermentation product
Industry: Non-Drug Biotech

Drug pipeline

1 asset

Bioalbumen

Pre-clinical

Partnerships

VTT Technical Research Centre of Finland (spin-off origin)

Beyond the preview

Go deeper on Onego Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Onego Bio.

Explore the full profile